Drug Profile
Research programme: influenza vaccines - AVANT Immunotherapeutics/Select Vaccines
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator AVANT Immunotherapeutics; Select Vaccines
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in Australia
- 16 Jul 2016 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA
- 14 Feb 2007 Preclinical trials in Influenza virus infections in Australia (unspecified route)